@entity10055 induces apoptosis in @entity157 xenografts in XXXX .

@entity1380 @entity49302 @entity1885 @entity19 @entity5 @entity4613 @entity1977 @entity185 @entity7349 @entity18253 @entity1379 @entity157 @entity10055
AIM: To evaluate the efficacy of @entity10055 ( @entity18253 ) as a chemotherapeutic agent for the treatment of @entity157 ( @entity157 ). METHODS: BALB/c @entity19 were randomized into four groups 24 h before subcutaneous injection of hepatocarcinoma BEL7402 cells suspended in @entity4613 buffered saline (PBS) into the right flank. The control group (n = 10) was fed a standard diet while treatment groups (n = 10 each) were fed a standard daily diet supplemented with different concentrations of @entity18253 (30, 50 and 70 mg/kg per day) for 21 d. @entity5 growth was measured once each week, and @entity5 volume (V) was calculated with the following equation: V = (L * W(2)) * 0.52, where L is the length and W is the width of the xenograft. After 21 d, @entity19 were killed under ether anesthesia, and @entity5 were excised and weighed. Apoptosis was evaluated through detection of DNA fragmentation with gel electrophoresis and the terminal deoxynucleotidyl transferase-mediated @entity1977 - @entity1885 nick end labeling (TUNEL) assay. Western blot analysis was performed to determine the expression of apoptosis-related proteins @entity1380 , @entity1379 , @entity49302 , cleaved @entity7349 , and cleaved @entity185 . RESULTS: @entity18253 suppressed @entity5 growth relative to controls. The mean @entity5 volumes were the following: control, 1090    89 mm(3); 30 mg/kg per day, 612    46 mm(3); 50 mg/kg per day, 563    38 mm(3); and 70 mg/kg per day, 221    26 mm(3). @entity5 volumes reached statistical significance relative to control xenografts (30 mg/kg per day, P < 0.05; 50 mg/kg per day, P < 0.05; 70 mg/kg per day, P < 0.01). Increasing concentrations of @entity18253 led to increased DNA fragmentation observed on gel electrophoresis and in the TUNEL assay (control, 1.6%    0.3%; 30 mg/kg per day, 2.9%    0.5%; 50 mg/kg per day, 3.15%    0.7%, and 70 mg/kg per day, 4.86%    0.9%). Western blot analysis revealed increased expression of @entity1380 , @entity49302 , cleaved- @entity7349 and cleaved- @entity185 proteins, which induce apoptosis, but decreased expression of @entity1379 protein, which is an inhibitor of apoptosis, following administration of @entity18253 . CONCLUSION: @entity18253 suppresses growth of BEL7402 @entity157 cells in vivo, in part through apoptosis induction, and is thus a candidate for therapeutic treatment of @entity157 .
